We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Novel Blood Test Detects Hidden Inflammation Across Multiple Diseases

By LabMedica International staff writers
Posted on 07 Feb 2025
Print article
Image: The research paves the way for the development of blood tests to detect disease-specific biomarkers (Photo courtesy of 123RF)
Image: The research paves the way for the development of blood tests to detect disease-specific biomarkers (Photo courtesy of 123RF)

Inflammation is a key factor in almost every disease, yet existing blood tests are unable to specify which organs or tissues are affected. In a groundbreaking discovery that could revolutionize how doctors diagnose and monitor a variety of conditions, researchers have now identified unique chemical markers that could enable blood tests to detect inflammation in specific organs.

The research, conducted by scientists at Case Western Reserve University (Cleveland, OH, USA), focuses on compounds that form during inflammatory processes, leaving distinct chemical signatures in different parts of the body. Their work centers around how reactive oxygen species (ROS)—highly reactive molecules generated by immune cells to combat pathogens—interact with fatty acids in cell membranes. This interaction leads to the creation of compounds known as epoxyketooctadecanoic acids (EKODEs). These compounds accumulate in different tissues experiencing oxidative stress, such as the brain, heart, and liver. To further understand this, the researchers synthesized model compounds and systematically studied their interactions with various amino acids, ultimately discovering that the amino acid cysteine formed stable bonds with EKODEs.

The findings, published in Proceedings of the National Academy of Sciences (PNAS), were validated through experiments involving both mouse models and human tissues. The team developed antibodies that could detect the different types of EKODEs and measure their varying concentrations across various organs. This marks a shift in how researchers could potentially identify disease-specific biomarkers. The implications of this discovery extend beyond merely detection. The method could serve as a model similar to the widely used A1C test for diabetes, which tracks blood sugar levels over three months by measuring glucose-bound hemoglobin. Likewise, an EKODE-based test could reveal abnormal oxidative stress patterns specific to particular organs, potentially identifying early signs of conditions such as heart disease, Alzheimer's, and cancers before they become severe.

The research team is currently focused on discovering EKODE markers related to eye diseases like age-related macular degeneration and diabetic retinopathy. These conditions, which can lead to vision loss, could be detected earlier through blood tests based on this new research. Moving forward, the next phase of the research will involve linking specific EKODE patterns to distinct diseases, which could lead to a new class of diagnostic tools capable of detecting inflammation with remarkable accuracy. For both patients and healthcare providers, this could enable earlier diagnosis and more targeted treatments for a wide range of inflammatory diseases. The research has also captured the interest of pharmaceutical companies, as identifying reactive cysteines is becoming increasingly crucial in drug development.

“This research opens up an amazing number of pathways for future studies,” said Greg Tochtrop, professor of chemistry at Case Western Reserve who led the investigation. “It will lead directly to better understanding inflammation and detecting diseases, as well as to discovering new drugs.”

New
Gold Member
Human Chorionic Gonadotropin Test
hCG Quantitative - R012
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Cytomegalovirus Real-Time PCR Test
Quanty CMV Virus System
New
Silver Member
H-FABP Assay
Heart-Type Fatty Acid-Binding Protein Assay

Print article

Channels

Clinical Chemistry

view channel
Image: Professor Nicole Strittmatter (left) and first author Wei Chen stand in front of the mass spectrometer with a tissue sample (Photo courtesy of Robert Reich/TUM)

Mass Spectrometry Detects Bacteria Without Time-Consuming Isolation and Multiplication

Speed and accuracy are essential when diagnosing diseases. Traditionally, diagnosing bacterial infections involves the labor-intensive process of isolating pathogens and cultivating bacterial cultures,... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: The new algorithms can help predict which patients have undiagnosed cancer (Photo courtesy of Adobe Stock)

Advanced Predictive Algorithms Identify Patients Having Undiagnosed Cancer

Two newly developed advanced predictive algorithms leverage a person’s health conditions and basic blood test results to accurately predict the likelihood of having an undiagnosed cancer, including ch... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.